KCM
AEON icon

Kawa Capital Management’s AEON Biopharma AEON Stock Holding History

Kawa Capital Management’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-972
Closed -$686K – 1
2022
Q2 		$686K Hold
972
– – 3.2% 13
2022
Q1 		$684K Hold
972
– – 1.14% 29
2021
Q4 		$679K Buy
+972
New +$683K 0.65% 43

Other funds holding AEON

ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Kawa Capital Management's AEON Position: Q3 2022 in Review

Kawa Capital Management sold out of AEON Biopharma (AEON) in Q3 2022, closing a stake of 972 shares — an estimated $686K sold.

Kawa Capital Management first reported a position in AEON in Q4 2021 and held it in 3 quarters. The position peaked at $686K in Q2 2022. 81 funds tracked by Wall St. Rank hold AEON as of Q3 2022.

  • Kawa Capital Management reported no remaining AEON Biopharma position as of Q3 2022 after selling out during the quarter.
  • Kawa Capital Management sold 972 AEON Biopharma shares in Q3 2022, an estimated $686K.
  • Kawa Capital Management first reported a position in AEON Biopharma in Q4 2021 and held it in 3 quarters.
  • Kawa Capital Management's AEON Biopharma position peaked at $686K in Q2 2022.
  • 81 funds tracked by Wall St. Rank held AEON Biopharma as of Q3 2022.

Based on Kawa Capital Management's 13F filing for Q3 2022.